Suppr超能文献

抗体在体外血清水平完全中和的情况下,可保护猕猴免受致病性R5猿猴/人类免疫缺陷病毒的阴道攻击。

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

作者信息

Parren P W, Marx P A, Hessell A J, Luckay A, Harouse J, Cheng-Mayer C, Moore J P, Burton D R

机构信息

Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA.

出版信息

J Virol. 2001 Sep;75(17):8340-7. doi: 10.1128/jvi.75.17.8340-8347.2001.

Abstract

A major unknown in human immunodeficiency virus (HIV-1) vaccine design is the efficacy of antibodies in preventing mucosal transmission of R5 viruses. These viruses, which use CCR5 as a coreceptor, appear to have a selective advantage in transmission of HIV-1 in humans. Hence R5 viruses predominate during primary infection and persist throughout the course of disease in most infected people. Vaginal challenge of macaques with chimeric simian/human immunodeficiency viruses (SHIV) is perhaps one of the best available animal models for human HIV-1 infection. Passive transfer studies are widely used to establish the conditions for antibody protection against viral challenge. Here we show that passive intravenous transfer of the human neutralizing monoclonal antibody b12 provides dose-dependent protection to macaques vaginally challenged with the R5 virus SHIV(162P4). Four of four monkeys given 25 mg of b12 per kg of body weight 6 h prior to challenge showed no evidence of viral infection (sterile protection). Two of four monkeys given 5 mg of b12/kg were similarly protected, whereas the other two showed significantly reduced and delayed plasma viremia compared to control animals. In contrast, all four monkeys treated with a dose of 1 mg/kg became infected with viremia levels close to those for control animals. Antibody b12 serum concentrations at the time of virus challenge corresponded to approximately 400 (25 mg/kg), 80 (5 mg/kg), and 16 (1 mg/kg) times the in vitro (90%) neutralization titers. Therefore, complete protection against mucosal challenge with an R5 SHIV required essentially complete neutralization of the infecting virus. This suggests that a vaccine based on antibody alone would need to sustain serum neutralizing antibody titers (90%) of the order of 1:400 to achieve sterile protection but that lower titers, around 1:100, could provide a significant benefit. The significance of such substerilizing neutralizing antibody titers in the context of a potent cellular immune response is an important area for further study.

摘要

人类免疫缺陷病毒(HIV-1)疫苗设计中的一个主要未知因素是抗体在预防R5病毒黏膜传播方面的功效。这些利用CCR5作为共受体的病毒,似乎在人类HIV-1传播中具有选择性优势。因此,R5病毒在初次感染期间占主导地位,并在大多数感染者的病程中持续存在。用嵌合猿猴/人类免疫缺陷病毒(SHIV)对猕猴进行阴道攻毒,可能是人类HIV-1感染的最佳可用动物模型之一。被动转移研究被广泛用于确定抗体保护免受病毒攻击的条件。在此,我们表明,人源中和单克隆抗体b12的被动静脉内转移为经R5病毒SHIV(162P4)阴道攻毒的猕猴提供了剂量依赖性保护。在攻毒前6小时给予每千克体重25毫克b12的四只猴子中,四只均未出现病毒感染迹象(无菌保护)。给予每千克体重5毫克b12的四只猴子中有两只同样受到保护,而另外两只与对照动物相比,血浆病毒血症明显降低且延迟出现。相比之下,接受每千克体重1毫克剂量治疗的四只猴子均感染,病毒血症水平接近对照动物。病毒攻毒时抗体b12的血清浓度分别约为体外(90%)中和效价的400倍(25毫克/千克)、80倍(5毫克/千克)和16倍(1毫克/千克)。因此,针对R5 SHIV的黏膜攻毒实现完全保护基本上需要对感染病毒进行完全中和。这表明,仅基于抗体的疫苗需要维持约1:400的血清中和抗体效价(90%)以实现无菌保护,但较低的效价,约为1:100,可能会带来显著益处。在有效的细胞免疫反应背景下,这种亚无菌中和抗体效价的意义是一个需要进一步研究的重要领域。

相似文献

6
Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
Transfus Clin Biol. 2001 Aug;8(4):350-8. doi: 10.1016/s1246-7820(01)00187-2.

引用本文的文献

1
Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques.
Front Microbiol. 2025 Jun 2;16:1592647. doi: 10.3389/fmicb.2025.1592647. eCollection 2025.
2
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.
Vaccines (Basel). 2025 Jan 31;13(2):148. doi: 10.3390/vaccines13020148.
3
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.
Front Immunol. 2024 Nov 7;15:1478703. doi: 10.3389/fimmu.2024.1478703. eCollection 2024.
4
Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells.
PLoS Pathog. 2024 Oct 28;20(10):e1012665. doi: 10.1371/journal.ppat.1012665. eCollection 2024 Oct.
6
PET/CT Targeted Tissue Sampling Reveals Intravenously Administered HGN194 IgG1 Affects HIV Distribution after Rectal Exposure.
AIDS Res Hum Retroviruses. 2024 Nov;40(11):637-648. doi: 10.1089/AID.2024.0019. Epub 2024 Aug 28.
7
Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs.
iScience. 2024 May 28;27(7):110141. doi: 10.1016/j.isci.2024.110141. eCollection 2024 Jul 19.
9
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0015222. doi: 10.1128/cmr.00152-22. Epub 2024 Apr 30.
10
HIV-1 neutralizing antibodies provide sterilizing immunity by blocking infection of the first cells.
Cell Rep Med. 2023 Oct 17;4(10):101201. doi: 10.1016/j.xcrm.2023.101201. Epub 2023 Oct 6.

本文引用的文献

2
The antiviral activity of antibodies in vitro and in vivo.
Adv Immunol. 2001;77:195-262. doi: 10.1016/s0065-2776(01)77018-6.
4
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
Science. 2000 Oct 20;290(5491):486-92. doi: 10.1126/science.290.5491.486.
9
IgG surfaces as an important component in mucosal protection.
Nat Med. 2000 Feb;6(2):129-30. doi: 10.1038/72206.
10
In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein.
J Med Primatol. 1999 Aug-Oct;28(4-5):164-8. doi: 10.1111/j.1600-0684.1999.tb00265.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验